KDR inhibitor with the intramolecular non-bonded interaction: Conformation-activity relationships of novel indole-3-carboxamide derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 6, 2011, Pages 1782-1785

  Honda, Takahiro ^a,b   Nagahara, Hironori ^b   Mogi, Hiroyuki ^a,b   Ban, Masakazu ^a,b   Aono, Hiroyuki ^a,b  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Indole; Intramolecular hydrogen bonding; Intramolecular non bonded interaction; KDR inhibitor; Non bonded S O interaction; Pseudo ring design; X ray crystallography

Indexed keywords

INDOLE 3 CARBOXAMIDE DERIVATIVE; INDOLE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG SYNTHESIS; HYDROGEN BOND; IC 50; MOLECULAR INTERACTION; SULFUR OXYGEN INTERACTION; X RAY CRYSTALLOGRAPHY;

ENZYME INHIBITORS; INDOLES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79952362184     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.063     Document Type: Article

References (28)

1. T. Honda, H. Tajima, Y. Kaneko, M. Ban, T. Inaba, Y. Takeno, K. Okamoto, and H. Aono Bioorg. Med. Chem. Lett. 18 2008 2939
2. J. Taunton Chem. Biol. 4 1997 493
3. M. Klagsbrun, and M.A. Moses Chem. Biol. 6 1999 R217
4. P.W. Manley, G. Bold, J. Bruggen, G. Fendrich, P. Furet, J. Mestan, C. Schnell, B. Stolz, T. Meyer, B. Meyhack, W. Stark, A. Strauss, and J. Wood Biochim. Biophys. Acta 17 2004 1697
5. O.A. Anderson, J.W.B. Bainbridge, and D.T. Shima Drug Discovery Today 15 2010 272
6. A. Kiselyov, K.V. Balakin, and S.E. Tkachenko Expert Opin. Investig. Drugs 16 2007 83
7. G. Bold, J. Frei, P. Furet, P.W. Manley, J. Bruggen, R. Cozens, S. Ferrari, F. Hofmann, G. Martiny-Baron, J. Mestan, T. Meyer, and J.M. Wood Drugs Future 27 2002 43
8. P.W. Manley, P. Furet, G. Bold, J. Bruggen, J. Mestan, T. Meyer, C.R. Schnell, J. Wood, M. Haberey, A. Huth, A. Menrad, E. Ottow, D. Seidelmann, G. Siemeister, and K.-H. Thierauch J. Med. Chem. 45 2002 5687
9. P. Furet, G. Bold, F. Hofmann, P. Manley, T. Meyer, and K.-H. Altmann Bioorg. Med. Chem. Lett. 13 2003 2967
10. J. Dumas, and J.A. Dixon Exp. Opin. Ther. Pat. 15 2005 647
11. Y. Nagao, T. Hirata, S. Goto, S. Sano, A. Kakehi, K. Iizuka, and M. Shiro J. Am. Chem. Soc. 120 1998 3104
12. R. Tanaka, Y. Oyama, S. Imajo, S. Matsuki, and M. Ishiguro Bioorg. Med. Chem. Lett. 5 1997 1389
13. M. Ishiguro, T. Nishihara, and R. Tanaka Yakugaku Zasshi 121 2001 915
14. N. Haginoya, S. Kobayashi, S. Komoriya, T. Yoshino, M. Suzuki, T. Shimada, K. Watanabe, Y. Hirokawa, T. Furugori, and T. Nagahara J. Med. Chem. 47 2004 5167
15. Kucsman, A.; Kapovits, I. In Organic Sulfur Chemistry: Theoretical and experimental Advances. Bernardi, F.; Csizmadia, I.G., Mangini, A. Eds.; Elsevier: Amsterdam, 1985; Vol. 19, pp 191-245.
16. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Science 289 2000 1938
17. C.P. Mol, D. Fabbro, and D.J. Hosfield Curr. Opin. Drug Discov. Devel. 7 2004 639
18. J.I. Levin, E. Turos, and S.M. Weinreb Synth. Commun. 12 1982 989
19. S. Nakatsuka, T. Masuda, O. Asano, T. Teramae, and T. Goto Tetrahedron Lett. 27 1986 4327
20. T. Itoh, and T. Mase Org. Lett. 6 2004 4587
21. F. Yamada, M. Tamura, and M. Somei Heterocycles 49 1998 451
22. Structure of compound 14 was confirmed by X-ray crystallographic analysis. See Supplementary data.
23. A. Cipiciani, S. Clementi, G. Giulietti, G. Marino, G. Savelli, and P. Linda J. Chem. Soc. Perkin 2 1982 523
24. X-ray crystallographic analyses data of them (CCDC Number #790833 for 5d, #790834 for 6c and #790835 for 7d) were deposited with Cambridge Crystallographic Data Center.
25. Recently IKKβ inhibitors possessing 1-6 non-bonded S-O interactions were reported by the researchers of Takeda Pharm. Co. Ltd H. Sugiyama, M. Yoshida, K. Mori, T. Kawamoto, S. Sogabe, T. Takagi, H. Oki, T. Tanaka, H. Kimura, and Y. Ikeura Chem. Pharm. Bull. 55 2007 613
26. KDR inhibitory activity assay was performed by the ELISA method by measuring the phosphorylation level of biotinylated peptide including Tyr in the sequence.
27. P. Furet, G. Caravatti, V. Gaugano, M. Lang, T. Meyer, and J. Shoepfer Bioorg. Med. Chem. Lett. 18 2008 897
28. H. Nakamura, Y. Sasaki, M. Uno, T. Yoshikawa, T. Asano, H.S. Ban, H. Fukazawa, M. Shibuya, and Y. Uehara Bioorg. Med. Chem. Lett. 16 2006 5127